TARS · Company research
Tarsus Pharmaceuticals, Inc. Common Stock (TARS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals (TARS) Institutional Ownership 2026 $TARS - MarketBeat | Tarsus Pharmaceuticals (TARS) Institutional Ownership 2026 $TARS MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| Liquidity Mapping Around (TARS) Price Events - Stock Traders Daily | Liquidity Mapping Around (TARS) Price Events Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 14, 2026 | neutral | 0 | 0.6 |
| Tarsus Pharmaceuticals (TARS) Selling Stockholders Plan to Offlo - GuruFocus | Tarsus Pharmaceuticals (TARS) Selling Stockholders Plan to Offlo GuruFocus | View source ↗ | GuruFocus | Oct 13, 2026 | neutral | 0 | 0.6 |
| Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options - Seeking Alpha | Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options Seeking Alpha | View source ↗ | Seeking Alpha | Oct 6, 2026 | neutral | 0 | 0.6 |
| Tiny mites cause over two-thirds of blepharitis cases, an eyelid disease. Tarsus plans 11 presentations. - Stock Titan | Tiny mites cause over two-thirds of blepharitis cases, an eyelid disease. Tarsus plans 11 presentations. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Nearly $1M Tarsus (NASDAQ: TARS) insider share sale planned by a company director - Stock Titan | Nearly $1M Tarsus (NASDAQ: TARS) insider share sale planned by a company director Stock Titan | View source ↗ | Stock Titan | Sep 15, 2026 | neutral | 0 | 0.6 |
| Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Simply Wall Street | Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? Simply Wall Street | View source ↗ | Simply Wall Street | Aug 18, 2026 | neutral | 0 | 0.6 |
| Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance | Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak Yahoo Finance | View source ↗ | Yahoo Finance | Aug 13, 2026 | neutral | 0 | 0.6 |
| Tarsus Pharmaceuticals (TARS) Stock Can Revenue Momentum Outrun Rising Costs - Simply Wall Street | Tarsus Pharmaceuticals (TARS) Stock Can Revenue Momentum Outrun Rising Costs Simply Wall Street | View source ↗ | Simply Wall Street | Aug 8, 2026 | neutral | 0 | 0.6 |
| Tarsus to Raise About $125M, Selling Stock at $56 a Share - Stock Titan | Tarsus to Raise About $125M, Selling Stock at $56 a Share Stock Titan | View source ↗ | Stock Titan | Aug 6, 2026 | neutral | 0 | 0.6 |
| Tarsus Pharmaceuticals to Host Second Quarter 2026 Financial Results Webcast and Corporate Update - Quiver Quantitative | Tarsus Pharmaceuticals to Host Second Quarter 2026 Financial Results Webcast and Corporate Update Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 6, 2026 | neutral | 0 | 0.6 |
| Top Tarsus commercial executive departs as eye drug XDEMVY gains traction - Stock Titan | Top Tarsus commercial executive departs as eye drug XDEMVY gains traction Stock Titan | View source ↗ | Stock Titan | Jul 13, 2026 | neutral | 0 | 0.6 |
| TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Yahoo Finance | TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme Yahoo Finance | View source ↗ | Yahoo Finance | Jul 1, 2026 | neutral | 0 | 0.6 |
| TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits | TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme Stocktwits | View source ↗ | Stocktwits | Jul 1, 2026 | neutral | 0 | 0.6 |
| Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings? - Yahoo Finance | Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings? Yahoo Finance | View source ↗ | Yahoo Finance | May 11, 2026 | neutral | 0 | 0.6 |
| Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains - Yahoo Finance | Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains Yahoo Finance | View source ↗ | Yahoo Finance | May 11, 2026 | neutral | 0 | 0.6 |
| Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses - Yahoo Finance | Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses Yahoo Finance | View source ↗ | Yahoo Finance | Apr 3, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.